Advaxis Scientists Publish Research of Listeria Monocytogenes-Based Vaccine for Prostate Cancer in Latest Edition of Cancer Immunology & Immunotherapy
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Mar 4, 2008 - Drs. Vafa Shahabi (Advaxis Inc. OTCBB: ADXS) and Yvonne Paterson (University of Pennsylvania) led a team (the "Team") of six leading research microbiologists and published findings on the potential use of a Listeria monocytogenes-based vaccine for prostate cancer ("pCa").The Team developed and characterized a recombinant live attenuated Listeria monocytogenes/PSA ("Lm-LLO-PSA") vaccine with potential use for the treatment of pCa. Results indicated that Lm-LLO-PSA is a likely candidate for pCa immunotherapy.
"The Team's findings support the opportunity for immunotherapy in treating prostate cancer," said Thomas Moore chairman and chief executive officer of Advaxis. "The results build upon Drs. Shahabi's and Paterson's vaccine work currently under development at Advaxis. We look forward to additional research in this area as it can be instrumental in Advaxis' patented Lm delivery platform."
About Advaxis, Inc.
Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes ("Lm") cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis' scientific advisory board. Advaxis is developing therapeutic cancer vaccines that enhance the immune system's cancer-fighting abilities through its proprietary Lm based system, which utilizes multiple simultaneous immunological mechanisms to develop safer and more effective Lm based cancer vaccines. Advaxis is the exclusive licensee of a patented broadly enabling Lm platform technology that can elicit effective anti-tumor responses.
Advaxis' lead Lm vaccine candidate - Lovaxin C - targets cervical and head and neck cancers. Current Lm vaccines in development target breast, ovarian and lung cancers. Advaxis has completed a Phase I/II clinical trial. The Lm platform will also have applications in the fields of infectious disease and autoimmune disorders.
About Lovaxin C Vaccine
Advaxis' Listeria technology platform uses modified Listeria monocytogenes ("Lm") to deliver a tumor-specific antigen fusion protein. Lm has the ability to generate a robust immune response and produce an unusually strong and effective therapeutic immune response to existing cancers and other diseases affecting many related immune mechanisms, simultaneously and in integrated fashion.
Advaxis' Lm-based technology is mostly based on Dr. Yvonne Paterson's decade worth of work in her laboratory at the University of Pennsylvania. This technology she developed generates an unusually profound cytotoxic immune response capable of killing cancer cells. The Company's proprietary antigen fusion protein technology, also suppresses regulatory T cells that inhibit many vaccines in the creation of a local tumor environment, conducive to the therapeutic effects of the activated tumor-killing cells.
Lovaxin C was designed to treat women who have already developed cervical cancer as a result of contracting the human papilloma virus ("HPV"), unlike current products on the market that are ineffective in treating HPV-infected women.
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Contact
Advaxis, Inc.
Thomas A. Moore, 732-545-1590
moore@advaxis.com
OR
Investors:
Investor Relations Group
Conrad F. Mir, 212-825-3210
OR
Media:
Janet Vasquez/Michaela Heller, 212-825-3210
Clinical Trial Results Archive
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Dec
